WUSTL spinout Wugen has collected $172m in a series B round to progress its pipeline targeting several cancer indications.
Wugen, a US-based oncology therapy developer spun out of Washington University in St Louis, closed a $172m series B round co-led by Abingworth and Tybourne Capital Management on Thursday.
Alexandria Venture Investments, the venture capital arm of life sciences real estate investment trust Alexandria Real Estate Equities, took part in the round, as did financial services group Fidelity, Intermediate Capital Group (ICG), Sands Capital, Aisling Capital Management, Velosity Capital, Falcon Edge Capital, RiverVest Venture Partners, Lyzz Capital and Lightchain Capital.
Founded in 2018, Wugen is developing a pipeline of chimeric antigen receptor (CAR) T-cell and memory natural killer (NK) cell therapies for patients with solid tumours, acute myeloid leukaemia (AML) and T-cell malignancies. Its lead product candidate, WU-NK-101, has demonstrated the potential to be highly effective against AML.
The series B capital will go towards clinical development of the company’s memory NK cell technology platform and support…
